PRP Therapy for Smell Loss: Comparing Injection vs Non-Invasive Treatment Methods

This clinical trial addresses one of the most challenging aftereffects of viral infections like COVID-19: persistent smell loss. When people lose their sense of smell (a condition called anosmia) or have reduced smell function (hyposmia), it significantly impacts their quality of life, nutritional intake, and even safety, as they cannot detect smoke, gas leaks, or spoiled food. Current treatment options are limited, with smell training being the primary evidence-based approach, but many patients continue to struggle despite this therapy.

This study investigates an innovative treatment using the patient's own blood components to potentially regenerate smell function. Platelet-rich plasma (PRP) is created by concentrating platelets from a small sample of the patient's blood. These platelets contain numerous growth factors and healing substances that may help repair and regenerate the delicate nerve tissues responsible for smell detection in the nose. The research team is comparing two different methods of delivering this PRP treatment to determine which approach works better and is more comfortable for patients.

The first method involves injecting the PRP directly into the smell-sensitive area of the nose using a fine needle under local anesthesia. The second method uses a gentler approach where PRP-soaked absorbable sponges are placed in the nasal passages without any needles. Both procedures are performed with visual guidance using a small camera (endoscope) to ensure precise placement. All participants will continue their smell training exercises throughout the study period to maximize potential benefits.

This research is particularly important because smell disorders affect millions of people worldwide, especially after viral infections. The psychological impact of smell loss is substantial, often leading to depression, social isolation, and decreased enjoyment of food and life experiences. Many patients describe feeling disconnected from their environment and missing out on the emotional connections that scents provide, from the comfort of familiar home smells to the joy of seasonal aromas.

The study will carefully measure improvements using standardized smell tests, quality of life questionnaires, and assessments of mood and cognitive function. Researchers will also monitor how well patients tolerate each procedure and track any side effects. Participants will be followed for at least three months after treatment to evaluate both short-term and longer-lasting benefits.

This research represents an important step forward in developing effective treatments for smell disorders. By comparing two delivery methods, the study aims to identify not only which approach works better but also which method patients find more comfortable and acceptable. The results could help establish new treatment standards that balance effectiveness with patient comfort, potentially making regenerative treatments more accessible to people suffering from smell loss.

The importance of this research extends beyond the immediate study participants. smell disorders have been historically under-researched and often dismissed as a minor concern, despite their significant impact on quality of life. The COVID-19 pandemic brought renewed attention to this problem as millions experienced smell loss, highlighting the urgent need for effective treatments. This study contributes to the growing body of evidence supporting regenerative approaches and helps advance our understanding of how to effectively deliver treatments to the delicate nasal tissues responsible for smell detection.

For patients and caregivers considering participation, this study offers access to cutting-edge treatment under careful medical supervision. The research team includes experienced specialists who will ensure proper safety monitoring throughout the study period. The comparison of two different delivery methods also means that regardless of which group participants are assigned to, they will receive an active treatment rather than a placebo, though both groups will continue with the standard smell training that forms the foundation of current smell rehabilitation approaches.